Glycopyrrolate treatment of chronic drooling

Peter Blasco, Jean C K Stansbury

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Objective: To describe the use of glycopyrrolate in the control of drooling in children and young adults with cerebral palsy and related neurodevelopmental disabilities. Design: Prospective, open-label study of drug dosage parameters, response to therapy, and side effects. Follow-up ranged from 8 months to 4 years. Setting: Outpatient clinic of a rehabilitation hospital that is a regional referral center for children with disabilities. Patients: Forty children and young adults with motor and/or cognitive disabilities who were experiencing drooling to a severe degree. Intervention: Treatment with oral glycopyrrolate. Outcome Measures: Change in the quantity of drooling and side effects associated with treatment. Results: Thirty-six patients (90%) had reduced drooling in response to medication; 2 (5%) could not be assessed and 2 (5%) received no benefit. Side effects resulted in discontinuation of treatment in 11 (28%). Overall, 26 (65%) continued to receive drug therapy because of the perceived benefit. The final effective dose ranged widely from 0.01 to 0.82 mg/kg per day. Conclusions: Glycopyrrolate therapy safely and effectively decreased but rarely abolished drooling in patients with cerebral palsy and related neurodevelopmental disabilities. The dose range was surprisingly broad. Side effects, although generally minor and predictable, often led to discontinuation of drug therapy.

Original languageEnglish (US)
Pages (from-to)932-935
Number of pages4
JournalArchives of Pediatrics and Adolescent Medicine
Volume150
Issue number9
StatePublished - Sep 1996
Externally publishedYes

Fingerprint

Glycopyrrolate
Sialorrhea
Cerebral Palsy
Young Adult
Therapeutics
Drug Therapy
Disabled Children
Ambulatory Care Facilities
Referral and Consultation
Rehabilitation
Outcome Assessment (Health Care)
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Blasco, P., & Stansbury, J. C. K. (1996). Glycopyrrolate treatment of chronic drooling. Archives of Pediatrics and Adolescent Medicine, 150(9), 932-935.

Glycopyrrolate treatment of chronic drooling. / Blasco, Peter; Stansbury, Jean C K.

In: Archives of Pediatrics and Adolescent Medicine, Vol. 150, No. 9, 09.1996, p. 932-935.

Research output: Contribution to journalArticle

Blasco, P & Stansbury, JCK 1996, 'Glycopyrrolate treatment of chronic drooling', Archives of Pediatrics and Adolescent Medicine, vol. 150, no. 9, pp. 932-935.
Blasco, Peter ; Stansbury, Jean C K. / Glycopyrrolate treatment of chronic drooling. In: Archives of Pediatrics and Adolescent Medicine. 1996 ; Vol. 150, No. 9. pp. 932-935.
@article{6f3e1f64403e456f9692367842b41f41,
title = "Glycopyrrolate treatment of chronic drooling",
abstract = "Objective: To describe the use of glycopyrrolate in the control of drooling in children and young adults with cerebral palsy and related neurodevelopmental disabilities. Design: Prospective, open-label study of drug dosage parameters, response to therapy, and side effects. Follow-up ranged from 8 months to 4 years. Setting: Outpatient clinic of a rehabilitation hospital that is a regional referral center for children with disabilities. Patients: Forty children and young adults with motor and/or cognitive disabilities who were experiencing drooling to a severe degree. Intervention: Treatment with oral glycopyrrolate. Outcome Measures: Change in the quantity of drooling and side effects associated with treatment. Results: Thirty-six patients (90{\%}) had reduced drooling in response to medication; 2 (5{\%}) could not be assessed and 2 (5{\%}) received no benefit. Side effects resulted in discontinuation of treatment in 11 (28{\%}). Overall, 26 (65{\%}) continued to receive drug therapy because of the perceived benefit. The final effective dose ranged widely from 0.01 to 0.82 mg/kg per day. Conclusions: Glycopyrrolate therapy safely and effectively decreased but rarely abolished drooling in patients with cerebral palsy and related neurodevelopmental disabilities. The dose range was surprisingly broad. Side effects, although generally minor and predictable, often led to discontinuation of drug therapy.",
author = "Peter Blasco and Stansbury, {Jean C K}",
year = "1996",
month = "9",
language = "English (US)",
volume = "150",
pages = "932--935",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Glycopyrrolate treatment of chronic drooling

AU - Blasco, Peter

AU - Stansbury, Jean C K

PY - 1996/9

Y1 - 1996/9

N2 - Objective: To describe the use of glycopyrrolate in the control of drooling in children and young adults with cerebral palsy and related neurodevelopmental disabilities. Design: Prospective, open-label study of drug dosage parameters, response to therapy, and side effects. Follow-up ranged from 8 months to 4 years. Setting: Outpatient clinic of a rehabilitation hospital that is a regional referral center for children with disabilities. Patients: Forty children and young adults with motor and/or cognitive disabilities who were experiencing drooling to a severe degree. Intervention: Treatment with oral glycopyrrolate. Outcome Measures: Change in the quantity of drooling and side effects associated with treatment. Results: Thirty-six patients (90%) had reduced drooling in response to medication; 2 (5%) could not be assessed and 2 (5%) received no benefit. Side effects resulted in discontinuation of treatment in 11 (28%). Overall, 26 (65%) continued to receive drug therapy because of the perceived benefit. The final effective dose ranged widely from 0.01 to 0.82 mg/kg per day. Conclusions: Glycopyrrolate therapy safely and effectively decreased but rarely abolished drooling in patients with cerebral palsy and related neurodevelopmental disabilities. The dose range was surprisingly broad. Side effects, although generally minor and predictable, often led to discontinuation of drug therapy.

AB - Objective: To describe the use of glycopyrrolate in the control of drooling in children and young adults with cerebral palsy and related neurodevelopmental disabilities. Design: Prospective, open-label study of drug dosage parameters, response to therapy, and side effects. Follow-up ranged from 8 months to 4 years. Setting: Outpatient clinic of a rehabilitation hospital that is a regional referral center for children with disabilities. Patients: Forty children and young adults with motor and/or cognitive disabilities who were experiencing drooling to a severe degree. Intervention: Treatment with oral glycopyrrolate. Outcome Measures: Change in the quantity of drooling and side effects associated with treatment. Results: Thirty-six patients (90%) had reduced drooling in response to medication; 2 (5%) could not be assessed and 2 (5%) received no benefit. Side effects resulted in discontinuation of treatment in 11 (28%). Overall, 26 (65%) continued to receive drug therapy because of the perceived benefit. The final effective dose ranged widely from 0.01 to 0.82 mg/kg per day. Conclusions: Glycopyrrolate therapy safely and effectively decreased but rarely abolished drooling in patients with cerebral palsy and related neurodevelopmental disabilities. The dose range was surprisingly broad. Side effects, although generally minor and predictable, often led to discontinuation of drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029810815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029810815&partnerID=8YFLogxK

M3 - Article

VL - 150

SP - 932

EP - 935

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 9

ER -